139 related articles for article (PubMed ID: 28516358)
1. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.
Gu JM; Zhao XY; Schwarz T; Schuhmacher J; Baumann A; Ho E; Subramanyan B; Tran K; Myles T; Patel C; Koellnberger M
AAPS J; 2017 Jul; 19(4):1186-1195. PubMed ID: 28516358
[TBL] [Abstract][Full Text] [Related]
2. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
[TBL] [Abstract][Full Text] [Related]
3. Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086.
Parng C; Singh P; Pittman DD; Wright K; Leary B; Patel-Hett S; Rakhe S; Stejskal J; Peraza M; Dufield D; Murphy JE; Webster R
J Pharm Sci; 2018 Jul; 107(7):1995-2004. PubMed ID: 29571739
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
[TBL] [Abstract][Full Text] [Related]
5. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor.
Hansen L; Petersen LC; Lauritzen B; Clausen JT; Grell SN; Agersø H; Sørensen BB; Hilden I; Almholt K
Thromb Res; 2014 Mar; 133(3):464-71. PubMed ID: 24393663
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.
Agersø H; Overgaard RV; Petersen MB; Hansen L; Hermit MB; Sørensen MH; Petersen LC; Hilden I
Eur J Pharm Sci; 2014 Jun; 56():65-9. PubMed ID: 24568891
[TBL] [Abstract][Full Text] [Related]
7. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
Yuan D; Rode F; Cao Y
Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
[TBL] [Abstract][Full Text] [Related]
8. Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Harder Delff P; Chowdary P
Haemophilia; 2019 Jan; 25(1):60-66. PubMed ID: 30408848
[TBL] [Abstract][Full Text] [Related]
9. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of monoclonal antibody against recombinant human tissue factor pathway inhibitor.
Yang Y; He X; Li J; He S
Chin Med J (Engl); 1998 Aug; 111(8):718-21. PubMed ID: 11245026
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
12. An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency.
Martin EJ; Nolte ME; Kuhn J; Schmidt N; Pfaff N; Brophy DF
Haemophilia; 2021 Jul; 27(4):690-698. PubMed ID: 33915599
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
14. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.
Chang JY; Chantrathammachart P; Monroe DM; Key NS
Thromb Res; 2012 Sep; 130(3):e151-7. PubMed ID: 22658294
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
16. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
17. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
18. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
Dudal S; Subramanian K; Flandre T; Law WS; Lowe PJ; Skerjanec A; Genin JC; Duval M; Piequet A; Cordier A; Jarai G; Van Heeke G; Taplin S; Krantz C; Jones S; Warren AP; Brennan FR; Sims J; Lloyd P
MAbs; 2015; 7(5):829-37. PubMed ID: 26230385
[TBL] [Abstract][Full Text] [Related]
19. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma.
Abumiya T; Enjyoji K; Kokawa T; Kamikubo Y; Kato H
J Biochem; 1995 Jul; 118(1):178-82. PubMed ID: 8537308
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of LDL-associated tissue factor pathway inhibitor.
Augustsson C; Hilden I; Petersen LC
Thromb Res; 2014 Jul; 134(1):132-7. PubMed ID: 24787991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
